Late stage pipeline
Focus on Innovation and Science to unlock mid-term potential
Pipeline updated as of May 2025
| Molecule name | Indication | Phase I | Phase II | Phase III | Registration | Geography |
|---|---|---|---|---|---|---|
| Life-cycle management (label extension) | ||||||
|
Sarecycline
|
Acne
|
|
|
|||
|
Tirbanibulin
|
Actinic keratosis (Large Field)
|
|
|
|||
|
Tildrakizumab
|
Psoriatic arthritis
|
|
|
|||
|
Lebrikizumab
|
Atopic Dermatitis pediatric
|
|
|
|||
| New molecular entities (NMEs) | ||||||
|
Anti-IL-1RAP mAb
|
Hidradenitis suppurativa
|
|
|
|||
|
Anti-IL-21 mAb
|
Inflammatory skin disease
|
|
|
|||
|
IL-2muFc
|
Inflammatory skin disease
|
|
*
|
|||
|
ZKN-013
|
Rare Dermatology (RDEB/JEB)**
|
|
|
|||
* Worldwide ex-Greater China
**RDEB / JEB - Recessive Dystrophic Epidermolysis Bullosa / Junctional Epidermolysis Bullosa.